HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target

Benzinga · 10/16 10:38
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 price target.